secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001213900-25-073870
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027
-----------------------------------------------------------------------------

- SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.
- Raised $3.85M in April 2025 warrant inducement financing; anticipates more capital through 2027.
- Amended Toray license extends cartridge manufacturing timeline to October 2026.
- SanyoSeiko engaged as CMO for Symphony analyzer; cartridge redevelopment via FDA-registered CMO.
- No detailed financial results disclosed; company pre-revenue with clinical and operational progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025073870/0001213900-25-073870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390025073870/ea0252557-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-073870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer